ImmunityBio, Inc. is a late stage immunotherapy company developing a broad pipeline of next generation therapies that drive immunogenic mechanisms for defeating cancer and infectious disease. The company's immunotherapy platform is designed to activate both the innate (natural killer cell and macrophage) and adaptive (T cell) immune systems to create long term "immunologi

ImmunityBio, Inc. is a late stage immunotherapy company developing a broad pipeline of next generation therapies that drive immunogenic mechanisms for defeating cancer and infectious disease. The company's immunotherapy platform is designed to activate both the innate (natural killer cell and macrophage) and adaptive (T cell) immune systems to create long term "immunologi

ImmunityBio, Inc. is a late stage immunotherapy company developing a broad pipeline of next generation therapies that drive immunogenic mechanisms for defeating cancer and infectious disease. The company's immunotherapy platform is designed to activate both the innate (natural killer cell and macrophage) and adaptive (T cell) immune systems to create long term "immunologi

ImmunityBio, Inc. is a late stage immunotherapy company developing a broad pipeline of next generation therapies that drive immunogenic mechanisms for defeating cancer and infectious disease. The company's immunotherapy platform is designed to activate both the innate (natural killer cell and macrophage) and adaptive (T cell) immune systems to create long term "immunologi

ImmunityBio, Inc. is a late stage immunotherapy company developing a broad pipeline of next generation therapies that drive immunogenic mechanisms for defeating cancer and infectious disease. The company's immunotherapy platform is designed to activate both the innate (natural killer cell and macrophage) and adaptive (T cell) immune systems to create long term "immunologi

ImmunityBio, Inc. is a late stage immunotherapy company developing a broad pipeline of next generation therapies that drive immunogenic mechanisms for defeating cancer and infectious disease. The company's immunotherapy platform is designed to activate both the innate (natural killer cell and macrophage) and adaptive (T cell) immune systems to create long term "immunologi

ImmunityBio, Inc. is a late stage immunotherapy company developing a broad pipeline of next generation therapies that drive immunogenic mechanisms for defeating cancer and infectious disease. The company's immunotherapy platform is designed to activate both the innate (natural killer cell and macrophage) and adaptive (T cell) immune systems to create long term "immunologi

ImmunityBio, Inc. is a late stage immunotherapy company developing a broad pipeline of next generation therapies that drive immunogenic mechanisms for defeating cancer and infectious disease. The company's immunotherapy platform is designed to activate both the innate (natural killer cell and macrophage) and adaptive (T cell) immune systems to create long term "immunologi

ImmunityBio, Inc. is a late stage immunotherapy company developing a broad pipeline of next generation therapies that drive immunogenic mechanisms for defeating cancer and infectious disease. The company's immunotherapy platform is designed to activate both the innate (natural killer cell and macrophage) and adaptive (T cell) immune systems to create long term "immunologi

ImmunityBio, Inc. is a late stage immunotherapy company developing a broad pipeline of next generation therapies that drive immunogenic mechanisms for defeating cancer and infectious disease. The company's immunotherapy platform is designed to activate both the innate (natural killer cell and macrophage) and adaptive (T cell) immune systems to create long term "immunologi

ImmunityBio, Inc. is a late stage immunotherapy company developing a broad pipeline of next generation therapies that drive immunogenic mechanisms for defeating cancer and infectious disease. The company's immunotherapy platform is designed to activate both the innate (natural killer cell and macrophage) and adaptive (T cell) immune systems to create long term "immunologi